查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863218

生物製造關鍵蛋白市場：依產品類型、原料、應用、最終用途及通路分類－2025-2030年全球預測

Vital Proteins for Biomanufacturing Market by Product Type, Source, Application, End-Use, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2030 年，生物製造領域必需蛋白質市場將成長至 948.1 億美元，複合年成長率為 9.00%。

關鍵市場統計數據
基準年 2024 565.2億美元
預計年份：2025年 614.7億美元
2030 年預測 948.1億美元
複合年成長率 (%) 9.00%

本書權威概述了膠原蛋白、明膠和水解物如何助力現代生物製造工作流程並推動跨學科創新。

重要なタンパク質は、バイオ製造における基礎材料として機能し、幅広いライフサイエンスおよび商業用途に不可欠な構造的、機能的、生物活性特性を提供します。バイオ製造において、膠原蛋白、ゼラチン、および膠原蛋白由来加水分解物は重要な性能特性を提供します：膠原蛋白は組織の足場形成と機械的完全性を支え、ゼラチンは成形、カプセル化、制御放出を可能にし、加水分解物は製剤化や細胞シグナル伝達に適した可溶性生物活性ペプチドを提供します。これらの分類は一体となり、材料の複雑さの連続体を形成し、組織工学、ドラッグデリバリー、再生医療、機能性栄養学における革新を支えています。

隨著產業相關人員加速生物技術與材料科學的融合，這些蛋白質的作用正從普通原料擴展到工程化生物材料。這項轉變得益於重組表現系統、製程規模純化技術和客製化分子修飾技術的進步。因此，研究人員和製造商現在需要一致的分子譜、可追溯的原料和符合規範的生產路徑。重組和非傳統原料的引入正在重塑供應策略，而下游加工技術的改進則能夠生產出更高純度等級和性能最佳化的變體，以滿足臨床和高價值商業應用的嚴格要求。

鑑於這些趨勢，相關人員必須將材料性能與採購風險、監管趨勢和商業化時間表相匹配。有效的決策需要全面了解產品差異（按膠原蛋白類型和明膠分類）、水解物中分子量分佈的影響，以及材料規格與醫療設備、藥品和先進營養品等應用層面要求的匹配情況。

生物技術採購、永續性措施和先進加工技術如何融合，從而改變關鍵蛋白質應用中的供應鏈和材料性能

生物製造領域關鍵蛋白的格局正在經歷多項變革，這些變革正在重新定義上游採購和下游應用。首先，生物技術主導的採購正在加速重組蛋白和工程化表達平台的應用，這不僅減少了對傳統動物性原料的依賴，還提高了批次間的一致性，並實現了對功能域的序列級控制。這種轉變支持了對可追溯性和降低免疫抗原性風險有較高要求的醫療和製藥應用。其次，永續性的考量促使製造商更加重視海洋資源和產品特定的價值提升策略，以尋求低碳且符合倫理的替代方案。這些趨勢也與供應鏈多元化措施和新興的認證體系相互作用。

同時，材料科學和加工技術的進步正在拓展這些蛋白質的功能極限。精準的水解和分級分離技術使生產商能夠客製化分子量分佈和胜肽譜，從而最佳化生物活性、溶解度和流變學特性，以滿足特定應用的需求。此外，一體化製造模式將生物製程、配方和器械組裝緊密結合，促進材料和產品的協同開發，並縮短創新週期。監管政策的演變也扮演著重要角色。清晰的核准途徑和統一的醫用級材料品質標準，使得這些材料能夠迅速應用於植入式器械和組織工程構建體。這些轉變共同建構了一個生態系統，在這個系統中，材料創新、合乎倫理的採購和清晰的監管政策相互融合，創造了新的商業機會。

評估近期對蛋白質原料徵收的關稅如何影響整個供應鏈的籌資策略、庫存管理和創新重點。

近期影響蛋白質原料和中間投入品的貿易政策舉措，對採購、生產和購買決策產生了連鎖的營運和策略影響。對某些動物性和加工蛋白進口產品的關稅調整，增加了依賴跨境原料分銷的製造商的到岸成本，促使他們迅速重新評估供應商組合和合約條款。因此，一些公司優先考慮投資近岸外包、長期固定價格合約或國內加工能力，以維持生產的連續性並降低受監管終端用途的波動風險。

除了直接的成本影響外，關稅帶來的變化也影響了供應商的行為和庫存管理實踐。為了確保產品按時交付和監管可追溯性，製造商正在透過增加關鍵原料的安全庫存，並加快替代來源（包括海洋來源和重組來源）的合格來應對。此外，政策環境也促使製造商更加關注關稅分類和估值策略，並透過策略性路線規劃和利用自由貿易協定來最佳化入境物流，從而最大限度地降低關稅負擔。

重點，關稅也影響了創新選擇。面對更高的原料成本，一些開發商將研發預算重新分配到製程強化、良率提升以及單位價值所需原料較少的高價值產品配方上。因此，貿易措施的累積影響不僅限於短期成本上漲，也促使企業在籌資策略、製造投資和產品設計決策方面進行結構性調整，從而增強了企業的韌性和長期競爭力。

全面的細分分析表明，產品類型、採購方式、應用需求、最終用戶要求和分銷模式如何共同影響策略和規格決策。

細緻的細分框架揭示了不同產品類型、原料來源、應用、最終用途和分銷管道的獨特需求、風險特徵和商業策略。產品類型——膠原蛋白、明膠和水解物——的區分滿足了不同的技術規格和加工需求。在膠原蛋白中，I型、II型和III型的功能需要不同的分析控制和應用特異性；而在明膠中，A型和B型的分類會影響凝膠特性和配方行為。水解物根據其高低分子量分佈進行區分，在生物活性和溶解度方面表現出不同的性能特徵，直接影響醫療和營養應用領域的配方決策。

按來源進行細分突顯了傳統來源和新興來源之間的權衡取捨。牛、海源和豬源成分各自具有獨特的監管、文化和安全方面的考量。同時，重組生產技術可提供序列明確的成分，進而提高可追溯性並降低通用感染疾病風險。按應用進行細分則將材料選擇與最終功能緊密聯繫起來。動物營養配方需要客製化的胜肽譜以提高消化率和偏好，而化妝品則優先考慮護髮、口腔護理和護膚護膚的感官特性和皮膚相互作用特性。醫療設備開發商專注動態性能、植入相容性和傷口敷料性能，而營養保健品和藥品開發商則要求產品具備嚴格的生物活性、穩定性和遞送特性，以滿足骨骼、關節、皮膚、運動營養、藥物遞送和組織工程等應用的需求。

終端用途細分進一步細化了商業性管道，因為動物營養品、膳食補充劑、機能性食品、醫療應用和個人保健產品等不同領域的產品規格在管理體制、品質要求和通路經濟效益方面存在差異。分銷通路細分則凸顯了機構、線下和線上零售在包裝、標籤和供應節奏方面的不同要求。機構買家，例如餐飲服務和醫療保健機構，需要簽訂批量供應協議並持有嚴格的認證，而品牌網站和電商平台則強調直接面對消費者的銷售中的可追溯性和商店供貨情況。這些細分維度共同構成了一個技術和商業性考慮的矩陣，企業必須應對這些考量，才能使其產品開發、生產和上市策略保持一致。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和需求模式將決定採購、監管和商業化的優先事項。

區域趨勢持續影響關鍵蛋白質全球價值鏈的策略重點和競爭定位。在美洲，成熟的畜牧業和發達的水產養殖業為牛和豬肉原料的穩定供應提供了保障，而不斷成長的營養保健品和機能性食品市場則推動了對高純度水解物和膠原蛋白衍生物的需求，這些產品專為消費品量身定做。該地區的監管執法和自願性可追溯性計劃提高了品質預期，促使許多製造商投資於透明的供應鍊和認證體系，以促進跨境貿易和臨床應用。

在歐洲、中東和非洲，複雜的監管環境、永續性優先事項以及活性化的醫療設備產業共同推動了對符合倫理規範的海洋來源蛋白的需求。對環境合規和循環經濟的重視正在促進產品價值的提升和替代採購方式的開發，而監管機構之間的協調努力則為醫用級材料創建了清晰的供應管道。同時，亞太地區仍然是重要的生產和消費中心，這得益於其大規模的水產養殖業、不斷成長的美容和健康產品消費市場以及重組和海洋技術的快速應用。該地區成本效益高的製造基地，加上不斷增強的國內研發能力，使其成為原料出口中心以及成品和醫療設備開發的重要區域。

綜上所述，這些區域性洞察凸顯了多元化籌資策略、靈活的監管適應能力以及針對特定市場的產品定位的重要性。能夠使其生產基地、品管系統和分銷管道與區域需求特徵相符的企業，將更有利於掌握跨境機遇，並更好地應對當地的監管和消費趨勢。

現有製造商、特種原料公司和生技新興企業正在透過整合、差異化和策略聯盟競爭。

關鍵蛋白質領域的競爭動態呈現出複雜多樣的態勢，既有老牌生產商，也有特種原料製造商，還有利用生物技術的新興參與企業。老牌供應商持續投資於製程控制、認證和規模化生產，以滿足動物營養和大眾個人護理等大量應用的需求。同時，特種原料製造商則透過高純度醫用級產品、先進的分餾技術以及針對特定營養保健品和藥品應用的客製化胜肽開發來實現差異化競爭。而新興生技企業則透過引入重組表達平台和精準設計的序列，重塑了競爭格局，挑戰著傳統的採購模式。

策略方法正在多元化發展。一些公司正在建立整合原料採購、下游提純和配方服務的價值鏈，以提高利潤率並加快產品上市速度。另一些公司則採用輕資產模式，專注於專有配方、品牌建立和通路合作，以擴大其在直接面對消費者和機構管道的影響力。無需新增資本投資的併購、策略聯盟和契約製造合作正成為獲取技術能力和拓展地域覆蓋範圍的常見途徑。在整個競爭格局中，我們看到一個反覆出現的趨勢，即對可追溯性、品質體系和法規遵從性的重視，尤其是在面向醫療設備和製藥應用領域的供應商中。投資於健全的品管系統、透明的原料採購管道和技術支援服務的公司，能夠將自身定位為高價值、受監管客戶的首選合作夥伴。同時，優先考慮成本領先的公司則在大批量市場保持競爭優勢。

領導者可透過夥伴關係和有針對性的研發，採取切實可行的策略行動，降低供應風險，提升材料性能，並抓住高價值機會。

為因應供應波動、監管複雜性以及對先進蛋白質材料不斷變化的需求，產業領導者應優先採取一系列切實可行的措施。首先，投資多元化的籌資策略，將海洋來源、重組蛋白和產品特定來源與傳統來源結合，以降低對單一來源的依賴風險，並滿足不斷變化的客戶偏好。其次，加快製程改善和分析能力的提升，嚴格控制分子量分佈、交聯度和純度，從而提供符合醫療保健和製藥客戶嚴格要求的材料。第三，透過第三方認證、監管鏈文件和生命週期評估，加強品質、可追溯性和永續性的資格認證，以促進產品差異化和跨司法管轄區的市場准入。

此外，我們優先考慮策略合作夥伴關係和靈活的生產協議，以在不承擔過高資本風險的前提下實現快速規模化。我們選擇性地投資於高利潤應用領域的研發，這些領域材料科學和生物活性能夠提供可靠的產品優勢，例如組織工程支架、藥物遞送基質和經臨床檢驗的營養保健品。最後，我們透過為機構投資者提供配方支援、訂製包裝和技術培訓，同時發展面向消費者的直接行銷，強調產品的來源、功效和永續性，從而根據市場的具體需求調整我們的商業模式。這些措施的協同實施將增強業務永續營運，加速創新，並在不同的終端市場實現商業性回報最大化。

我們以實證為基礎的調查方法結合了專家訪談、技術文獻分析、供應鏈圖譜繪製和情境評估，從而提供可操作的洞見。

本分析的調查方法整合了多方面的證據，旨在為這一關鍵的蛋白質領域提供嚴謹而實用的觀點。主要定性資料包括對製造商、材料科學家、配方專家、法規顧問和通路合作夥伴的結構化訪談，以了解實際營運、技術限制和商業策略。次要研究涵蓋了同行評審的科學文獻、專利申請、標準文件和法規指南，檢驗技術聲明並整理醫療、製藥和消費品應用領域的法規環境。

分析過程包括將產品規格和應用需求進行交叉比對，以識別績效差距和機會；同時，供應鏈映射揭示了採購依賴性和物流薄弱環節。情境分析考察了各種現實發展趨勢，以檢驗其策略影響，包括政策和貿易發展、生產規模擴大路徑以及技術採納曲線。在整個調查方法中，我們強調對資訊來源，以確保結論的可靠性。對於受訪者觀點存在差異的情況，分析清晰地突出了共識和分歧點，旨在為知情決策提供支持，而不是僅做出單一預測。

一份權威、全面的分析報告，清楚闡述了將供應鏈韌性、材料工程和監管誠信轉化為競爭優勢的策略重點。

總之，生物技術、永續性和市場成熟度的結合，使得膠原蛋白、明膠和水解物在生物製造領域具有重要的戰略意義。這些材料不再只是普通的商品原料；它們是經過工程改造的組分，其分子特性、來源和監管狀態決定了它們在醫療、製藥和先進營養等領域的高價值應用。隨著供應鏈適應不斷變化的貿易政策，以及新的生產方法日益普及，那些將卓越技術與多元化的原料來源和清晰的品質文件相結合的公司將獲得更大的相對價值。

未來建構競爭優勢需要三個相互關聯的優先事項：建立可靠且檢驗資源集中於材料差異化能夠帶來可防禦的商業性優勢的領域，企業可以將當前的挑戰轉化為推動創新和下一代生物製造持續成長的催化劑。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用重組微生物平台進行生物製造，擴大無動物源膠原蛋白的生產規模
  • 整合先進的下游純化技術，以確保獲得用於細胞治療的高純度蛋白質支架。
  • 開發適用於人體組織構建體生物列印的水解海洋膠原蛋白變體
  • 採用永續的膠原蛋白支架交聯方法來提高其在生物反應器中的材料性能
  • 不斷完善的法規結構旨在簡化膠原蛋白基生物材料在臨床生產中的核准
  • 生技Start-Ups與大型膠原蛋白生產商之間的合作模式，旨在擴大組織工程應用規模
  • 引入即時監測工具，以實現基於蛋白質的生物製造過程中的持續品管
  • 利用纖連蛋白、層黏連蛋白和玻璃粘連蛋白擴大微載體和支架塗層的規模，以增強攪拌槽系統中的細胞附著。
  • 將控釋載體整合到生物反應器中，用於遞送不穩定的生長因子，從而提高給藥效率和均勻性。
  • 對符合GMP標準的重組生長因子的需求不斷成長，使得無血清、無異種成分的細胞培養能夠在工業規模上實現。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 生物製造市場（依產品類型分類）

  • 親和性和配體和結合蛋白質
    • 蛋白質A
    • 蛋白質G
    • 蛋白質L
    • 鏈黴親和素/親和素
  • 載體蛋白
    • 白蛋白
    • 鐵蛋白和其他
    • 轉鐵蛋白
  • Chaperone及折疊輔助工具
    • 伴侶蛋白
    • 蛋白質二硫鍵異構酶
  • 酵素
    • 糖苷酶
    • 激酶
    • 連接酶
    • 核酸酶
    • 聚合酵素
    • 蛋白酶
  • 細胞外基質和包被
    • 膠原蛋白
    • 纖連蛋白
    • 層黏連蛋白
    • 玻璃粘連蛋白
  • 生長因子和細胞激素
    • EGF家族
    • FGF家族
    • IGF/胰島素家族
    • 白細胞介素和趨化素
    • TGF-BETA/BMP家族
    • VEGF/PDGF家族
  • 血清替代
    • 成分明確的蛋白質混合物
    • 重組白蛋白混合物

第9章 生物製造市場（依來源分類）

  • 動物源性
  • 無細胞系統
  • 哺乳動物細胞系統
  • 微生物表現系統
  • 植物來源
  • 重組

第10章 生物製造市場（按應用分類）

  • 動物營養
    • 水產飼料
    • 牲畜飼料
    • 寵物食品
  • 化妝品
    • 護髮
    • 口腔清潔用品
    • 護膚
  • 醫療設備
    • 鷹架材料
    • 外科植入植入
    • 傷口敷料
  • 營養保健品
    • 骨骼健康
    • 關節健康
    • 皮膚健康
    • 運動營養
  • 製藥
    • 藥物輸送
    • 組織工程
    • 創傷治療

第11章 生物製造市場依最終用途分類

  • 學術和研究機構
  • 受託研究機構（CRO）
  • 製藥和生物技術公司

第12章 生物製造市場依通路分類

  • 直銷
  • 經銷商

第13章 各地區生物製造市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 生物製造市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國生物製造市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Danaher Corporation
    • Darling Ingredients Inc.
    • Gelita AG
    • Humabiologics, Inc
    • Lonza Group AG
    • Merck KGaA
    • Nitta Gelatin, Inc.
    • Thermo Fisher Scientific Inc.
    • Weishardt International
Product Code: MRR-D47730F51F28

The Vital Proteins for Biomanufacturing Market is projected to grow by USD 94.81 billion at a CAGR of 9.00% by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 56.52 billion
Estimated Year [2025] USD 61.47 billion
Forecast Year [2030] USD 94.81 billion
CAGR (%) 9.00%

An authoritative overview of how collagen, gelatin, and hydrolysates enable modern biomanufacturing workflows and drive crossdisciplinary innovation

Vital proteins function as foundational materials in biomanufacturing, supplying structural, functional, and bioactive properties essential to a broad array of life science and commercial applications. Within biomanufacturing, collagen, gelatin, and collagen-derived hydrolysates provide key performance attributes: collagen supports tissue scaffolding and mechanical integrity; gelatin enables molding, encapsulation, and controlled release; and hydrolysates offer soluble bioactive peptides suited to formulation and cellular signaling. Together, these classes form a continuum of material complexity that underpins innovations in tissue engineering, drug delivery, regenerative medicine, and functional nutrition.

As industry actors increasingly integrate biotechnology and materials science, the role of these proteins has expanded from commodity ingredients to engineered biomaterials. This transition has been driven by advances in recombinant expression systems, process-scale purification, and tailored molecular modification. Consequently, researchers and manufacturers now demand consistent molecular profiles, traceable raw materials, and regulatory-compliant production pathways. The introduction of recombinant and nontraditional sources is reshaping supply strategies, while downstream processing improvements are enabling higher-purity grades and performance-tuned variants that meet the rigorous needs of clinical and high-value commercial uses.

Given these dynamics, stakeholders must reconcile material performance with sourcing risk, regulatory trajectory, and commercialization timelines. Effective decision-making requires integrated visibility into product differentiation across collagen types and gelatin classes, the implications of molecular weight distributions in hydrolysates, and the alignment of material specifications with application-level requirements in medical devices, pharmaceuticals, and advanced nutrition.

How biotechnology sourcing, sustainability commitments, and advanced processing are converging to transform supply chains and material performance in vital protein applications

The landscape for vital proteins in biomanufacturing is undergoing several transformative shifts that are redefining both upstream sourcing and downstream application. First, biotechnology-driven sourcing is accelerating adoption of recombinant proteins and engineered expression platforms that reduce reliance on traditional animal sources while improving batch-to-batch consistency and enabling sequence-level control of functional domains. This shift, in turn, supports medical and pharmaceutical use-cases that demand traceability and reduced immunogenic risk. Second, sustainability considerations are elevating marine and byproduct valorization strategies as manufacturers seek lower-carbon, ethically aligned alternatives; these trends interact with supply chain diversification initiatives and new certification schemes.

Concurrently, advances in material science and processing are expanding the functional envelope of these proteins. Precision hydrolysis and fractionation techniques allow producers to tailor molecular weight distributions and peptide profiles to optimize bioactivity, solubility, and rheology for specific applications. In parallel, integrated manufacturing models are bringing bioprocessing, formulation, and device assembly closer together, facilitating co-development of materials and products and shortening innovation cycles. Regulatory evolution also plays a formative role: clearer pathways for medical-grade materials and harmonized quality standards are enabling faster adoption in implantable devices and tissue-engineering constructs. Altogether, these shifts are fostering an ecosystem where material innovation, ethical sourcing, and regulatory clarity converge to unlock new commercial opportunities.

Assessment of how recent tariff measures on protein inputs have propagated through supply chains to alter sourcing strategies, inventory management, and innovation priorities

Recent trade policy measures affecting proteinaceous raw materials and intermediate inputs have produced cascading operational and strategic effects across sourcing, manufacturing, and procurement decisions. Tariff adjustments imposed on certain animal-derived and processed protein imports have elevated landed costs for manufacturers that rely on cross-border raw material flows, prompting rapid reassessment of supplier portfolios and contract terms. As a result, some firms prioritized nearshoring, long-term fixed-priced contracts, or investment in domestic processing capabilities to mitigate volatility and maintain production continuity for regulated end uses.

Beyond direct cost effects, tariff-driven shifts have impacted supplier behavior and inventory management practices. Manufacturers have responded by increasing safety stocks for critical inputs and accelerating qualification of alternative sources, including marine and recombinant supply streams, to preserve product timelines and regulatory traceability. In addition, the policy environment has intensified focus on tariff classification and valuation strategies, as well as on optimizing inbound logistics to minimize duty exposure through strategic routing and free trade agreement utilization.

Importantly, tariffs also influenced innovation choices. Facing elevated input expense, some developers reallocated R&D budgets toward process intensification, yield improvements, and higher-value product formulations that reduce raw material intensity per unit of value. Consequently, the cumulative impact of trade measures extended beyond short-term cost inflation to encourage structural changes in sourcing strategies, manufacturing investments, and product design decisions that enhance resilience and long-term competitiveness.

Comprehensive segmentation analysis showing how product types, source variants, application demands, end-use requirements, and distribution models jointly shape strategy and specification decisions

A nuanced segmentation framework reveals differentiated requirements, risk profiles, and commercial strategies across product types, sources, applications, end uses, and distribution channels. Product type distinctions among collagen, gelatin, and hydrolysates correspond to divergent technical specifications and processing needs; within collagen, the functional roles of Type I, Type II, and Type III demand separate analytical controls and application focus, while gelatin classes Type A and Type B influence gelation properties and formulation behavior. Hydrolysates differentiated by high and low molecular weight profiles command distinct performance characteristics in bioactivity and solubility, which directly inform formulation decisions for medical versus nutritional applications.

Source-based segmentation highlights tradeoffs between traditional and emerging supply streams. Bovine, marine, and porcine origins each carry unique regulatory, cultural, and safety considerations, while recombinant production offers sequence-defined materials with enhanced traceability and reduced zoonotic risk. Application segmentation ties material selection tightly to end-function: animal nutrition formulations require tailored peptide profiles for digestibility and palatability; cosmetics prioritize sensory and skin interaction properties across hair care, oral care, and skin care; medical device developers focus on scaffold mechanics, implant compatibility, and wound dressing performance; nutraceuticals and pharmaceutical developers demand rigorous bioactivity, stability, and delivery characteristics for bone, joint, skin, sports nutrition, drug delivery, and tissue-engineering uses.

End-use segmentation further refines commercial pathways, as product specifications for animal nutrition, dietary supplements, functional foods, medical applications, and personal care diverge in regulatory regimes, quality expectations, and channel economics. Distribution channel segmentation underscores how institutional sales, offline retail, and online retail impose different packaging, labeling, and supply cadence requirements, with institutional buyers such as food service and healthcare institutions seeking bulk supply agreements and stringent certification, while brand websites and e-commerce platforms emphasize direct-to-consumer traceability and shelf-ready presentation. Together, these segmentation dimensions create a matrix of technical and commercial considerations that companies must navigate to align product development, manufacturing, and go-to-market strategies.

Regional dynamics and demand patterns across the Americas, Europe Middle East Africa, and Asia Pacific that determine sourcing, regulation, and commercialization priorities

Regional dynamics continue to shape strategic priorities and competitive positioning across the global value chain for vital proteins. In the Americas, established livestock industries and developed aquaculture sectors support a steady supply of bovine and porcine raw materials, while a growing nutraceutical and functional food market drives demand for high-purity hydrolysates and collagen derivatives tailored for consumer-facing formulations. Regulatory enforcement and voluntary traceability programs in this region reinforce quality expectations, prompting many manufacturers to invest in transparent supply chains and certification schemas that facilitate cross-border trade and clinical translation.

In Europe, Middle East, and Africa, a complex mix of regulatory jurisdictions, sustainability priorities, and rising medical device activity is accelerating demand for ethically sourced and marine-derived proteins. The region's emphasis on environmental compliance and circularity fosters innovation in byproduct valorization and alternative sourcing, while harmonization efforts across regulatory authorities create clearer pathways for medical-grade materials. Meanwhile, the Asia-Pacific region remains a major production and consumption hub, underpinned by large-scale aquaculture, expanding consumer markets for beauty and health products, and rapid adoption of recombinant and marine technologies. This region's cost-efficient manufacturing base, combined with rising domestic R&D capacity, positions it as both an exporter of raw materials and an increasingly sophisticated developer of finished formulations and devices.

Taken together, these regional insights emphasize the need for diversified sourcing strategies, regulatory agility, and market-specific product positioning. Companies that align production footprints, quality systems, and commercial channels with regional demand characteristics will be better equipped to capture cross-border opportunities and respond to localized regulatory and consumer trends.

Insights into how legacy producers, specialty ingredient firms, and biotech entrants are competing through integration, differentiation, and strategic collaboration

Competitive dynamics among companies in the vital proteins space reflect a blend of legacy producers, specialty ingredient firms, and new entrants leveraging biotechnology. Established suppliers continue to invest in process control, certification, and scale to serve high-volume applications such as animal nutrition and mass-market personal care, while specialty firms differentiate through high-purity medical-grade offerings, advanced fractionation capabilities, and custom peptide development for targeted nutraceutical and pharmaceutical uses. New biotechnology entrants are reshaping the competitive set by introducing recombinant expression platforms and precision-engineered sequences that challenge conventional sourcing assumptions.

Strategic approaches vary: some companies pursue integrated value chains that combine raw material sourcing, downstream purification, and formulation services to capture margin and accelerate time to market; others adopt asset-light models, focusing on proprietary formulations, branding, and channel partnerships to scale presence in direct-to-consumer and institutional channels. Mergers, strategic partnerships, and contract manufacturing collaborations have become common mechanisms to acquire technical capabilities or expand geographic reach without committing to greenfield capacity. Across the competitive landscape, one recurring theme is the premium placed on traceability, quality systems, and regulatory alignment, especially for suppliers targeting medical devices and pharmaceutical applications. Companies that invest in robust quality management systems, transparent provenance, and technical support services position themselves as preferred partners for high-value, regulated customers, while those prioritizing cost leadership maintain competitiveness in large-volume consumer segments.

Practical strategic actions for leaders to reduce supply risk, enhance material performance, and capture highvalue opportunities through partnerships and targeted R and D

Industry leaders should prioritize a set of pragmatic actions to navigate supply volatility, regulatory complexity, and shifting demand for advanced protein materials. First, invest in diversified sourcing strategies that combine traditional sources with marine, recombinant, and byproduct-derived streams to reduce exposure to single-source disruptions and to meet evolving customer preferences. Second, accelerate adoption of process improvements and analytical capabilities that enable tight control over molecular weight distribution, crosslinking, and purity, thereby delivering materials that meet the stringent requirements of medical and pharmaceutical customers. Third, strengthen quality, traceability, and sustainability credentials through third-party certification, chain-of-custody documentation, and lifecycle assessments to differentiate offerings and facilitate market access across jurisdictions.

Additionally, prioritize strategic partnerships and flexible manufacturing agreements to scale rapidly without incurring disproportionate capital risk. Invest selectively in R&D that targets high-margin applications where materials science and bioactivity confer defensible product advantages, such as tissue-engineered scaffolds, drug-delivery matrices, and clinically validated nutraceuticals. Finally, align commercial models with channel-specific needs by offering formulation support, tailored packaging, and technical training for institutional buyers, while developing direct-to-consumer narratives that emphasize provenance, efficacy, and sustainability. Implementing these actions in a coordinated manner will enhance resilience, accelerate innovation, and maximize commercial returns across a range of end markets.

An evidence driven methodology combining expert interviews, technical literature analysis, supply chain mapping, and scenario evaluation to support actionable insights

The research methodology underpinning this analysis integrates multiple evidence streams to produce a rigorous, actionable perspective on the vital proteins landscape. Primary qualitative inputs include structured interviews with manufacturers, material scientists, formulation experts, regulatory advisers, and channel partners to capture operational realities, technical constraints, and commercial strategies. Secondary review encompassed peer-reviewed scientific literature, patent filings, standards documentation, and regulatory guidance to validate technical assertions and to map the regulatory context for medical, pharmaceutical, and consumer applications.

Analytical processes involved crosswalks between product specifications and application requirements to identify performance gaps and opportunities, coupled with supply chain mapping to reveal sourcing dependencies and logistic vulnerabilities. Scenario analysis explored plausible policy and trade developments, manufacturing scale pathways, and technology adoption curves to assess strategic implications. Throughout the methodology, emphasis was placed on triangulation of findings and on documenting source provenance to ensure confidence in conclusions. Where heterogeneity existed in respondent perspectives, the analysis highlighted areas of consensus and divergence to support informed decision-making rather than singular predictive claims.

A decisive synthesis highlighting the strategic priorities that convert supply chain resilience, material engineering, and regulatory alignment into competitive advantage

In conclusion, the confluence of biotechnology, sustainability imperatives, and market sophistication is elevating the strategic importance of collagen, gelatin, and hydrolysates within biomanufacturing. These materials are no longer solely commodity inputs; they are engineered components whose molecular characteristics, provenance, and regulatory posture determine suitability for high-value applications in medicine, pharmaceuticals, and advanced nutrition. As supply chains adjust to trade policy shifts and as new production modalities gain traction, companies that marry technical excellence with diversified sourcing and clear quality documentation will capture disproportionate value.

Moving forward, the path to competitive advantage rests on three interconnected priorities: secure and verifiable supply chains, invest in process and analytical capabilities that deliver application-specific performance, and pursue market strategies that align product attributes with regional regulatory expectations and channel requirements. By focusing resources where material differentiation creates defensible commercial advantage, organizations can turn current disruptions into catalysts for innovation and sustainable growth in next-generation biomanufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of animal-free collagen production using recombinant microbial platforms for biomanufacturing
  • 5.2. Integration of advanced downstream purification technologies to ensure high-purity protein scaffolds for cell therapies
  • 5.3. Development of hydrolyzed marine collagen variants optimized for bioprinting human tissue constructs
  • 5.4. Adoption of sustainable cross-linking methods for collagen scaffolds to improve material performance in bioreactors
  • 5.5. Regulatory frameworks evolving to streamline approval of collagen-based biomaterials for clinical manufacturing
  • 5.6. Collaboration models between biotech startups and large-scale collagen producers to scale up tissue engineering applications
  • 5.7. Implementation of real-time monitoring tools for consistent quality control in protein-based biomanufacturing processes
  • 5.8. Expansion of microcarrier and scaffold coatings using fibronectin, laminin, and vitronectin to enhance cell attachment in stirred-tank systems
  • 5.9. Integration of controlled-release carriers to deliver labile growth factors within bioreactors, improving dosing efficiency and consistency
  • 5.10. Rising demand for GMP-grade recombinant growth factors to enable serum-free, xeno-free cell expansion at industrial scales

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vital Proteins for Biomanufacturing Market, by Product Type

  • 8.1. Affinity Ligands & Binding Proteins
    • 8.1.1. Protein A
    • 8.1.2. Protein G
    • 8.1.3. Protein L
    • 8.1.4. Streptavidin/Avidin
  • 8.2. Carrier Proteins
    • 8.2.1. Albumins
    • 8.2.2. Ferritin & Others
    • 8.2.3. Transferrins
  • 8.3. Chaperones & Folding Aids
    • 8.3.1. Chaperonins
    • 8.3.2. Protein Disulfide Isomerase
  • 8.4. Enzymes
    • 8.4.1. Glycosidases
    • 8.4.2. Kinases
    • 8.4.3. Ligases
    • 8.4.4. Nucleases
    • 8.4.5. Polymerases
    • 8.4.6. Proteases
  • 8.5. Extracellular Matrix & Coatings
    • 8.5.1. Collagens
    • 8.5.2. Fibronectins
    • 8.5.3. Laminins
    • 8.5.4. Vitronectin
  • 8.6. Growth Factors & Cytokines
    • 8.6.1. EGF Family
    • 8.6.2. FGF Family
    • 8.6.3. IGF/Insulin Family
    • 8.6.4. Interleukins & Chemokines
    • 8.6.5. TGF-Beta/BMP Family
    • 8.6.6. VEGF/PDGF Family
  • 8.7. Serum Replacements
    • 8.7.1. Defined Protein Mixes
    • 8.7.2. Recombinant Albumin Blends

9. Vital Proteins for Biomanufacturing Market, by Source

  • 9.1. Animal-Derived
  • 9.2. Cell-Free Systems
  • 9.3. Mammalian Cell Systems
  • 9.4. Microbial Expression Systems
  • 9.5. Plant-Based
  • 9.6. Recombinant

10. Vital Proteins for Biomanufacturing Market, by Application

  • 10.1. Animal Nutrition
    • 10.1.1. Aquaculture Feed
    • 10.1.2. Livestock Feed
    • 10.1.3. Pet Food
  • 10.2. Cosmetics
    • 10.2.1. Hair Care
    • 10.2.2. Oral Care
    • 10.2.3. Skin Care
  • 10.3. Medical Devices
    • 10.3.1. Scaffold Materials
    • 10.3.2. Surgical Implants
    • 10.3.3. Wound Dressings
  • 10.4. Nutraceuticals
    • 10.4.1. Bone Health
    • 10.4.2. Joint Health
    • 10.4.3. Skin Health
    • 10.4.4. Sports Nutrition
  • 10.5. Pharmaceuticals
    • 10.5.1. Drug Delivery
    • 10.5.2. Tissue Engineering
    • 10.5.3. Wound Healing

11. Vital Proteins for Biomanufacturing Market, by End-Use

  • 11.1. Academic & Research Institutions
  • 11.2. Contract Research Organizations (CROs)
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Vital Proteins for Biomanufacturing Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Vital Proteins for Biomanufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vital Proteins for Biomanufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vital Proteins for Biomanufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Danaher Corporation
    • 16.3.2. Darling Ingredients Inc.
    • 16.3.3. Gelita AG
    • 16.3.4. Humabiologics, Inc
    • 16.3.5. Lonza Group AG
    • 16.3.6. Merck KGaA
    • 16.3.7. Nitta Gelatin, Inc.
    • 16.3.8. Thermo Fisher Scientific Inc.
    • 16.3.9. Weishardt International

LIST OF FIGURES

  • FIGURE 1. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASEAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. GCC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. BRICS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. G7 VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. NATO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VITAL PROTEINS FOR BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 181. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 183. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 185. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 187. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 189. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 191. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 193. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 195. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 197. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 199. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 201. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 203. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 205. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2025-2030 (USD MILLION)
  • TABLE 207. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 209. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 211. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 213. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 215. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 217. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 221. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 223. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 225. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 227. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 229. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 231. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 233. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 235. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 237. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 239. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 241. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 243. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 245. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 247. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 249. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 251. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 253. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 255. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 257. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 259. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 261. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 263. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 265. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2025-2030 (USD MILLION)
  • TABLE 267. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 269. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 271. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. G